Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?

Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? by Farrell DJ published in J. Clin. Gastroenterol. 2013; 47 (3): 205-211